Jun 3, 2014 by Chris AhlstrandHas Melanoma Finally Met Its Match?Bristol and Merck both present impressive data at ASCO, but no clear-cut winner yet.
Apr 4, 2014 by Chris AhlstrandIs Biotech in a Bubble? The Bear Case ExplainedBiotech IPOs provide some powerful indications...
Mar 3, 2014 by Chris AhlstrandSarepta Therapeutics: Tale of a Biotech RollercoasterSarepta's roller coaster ride is not finished yet.
Feb 25, 2014 by Chris AhlstrandWhich Themes in Biotech Today are Bankable? RNAi is a new biotech technology investors need to watch.
Feb 21, 2014 by Chris AhlstrandDoes Bristol-Myers Squibb Co. Have Any Fuel Left in its Tank?An update on my prediction that Bristol-Myers Squibb will outperform in 2014.
Feb 9, 2014 by Chris AhlstrandAn Early Look at Some 2014 Biotech PredictionsAn Early Look at Some 2014 Predictions of Bristol, Vertex, Sarepta and Innate Pharma.
Jan 26, 2014 by Chris AhlstrandDissecting Bristol-Myers Squibb's 4th Quarter Earnings CallDissecting Bristol-Myers Squibb's 4th quarter earnings call.
Jan 23, 2014 by Chris AhlstrandCan Biotech Keep Flying High?Where does the biotech sector stand today?
